english.prescrire.org > Annual Prescrire Awards > The Prescrire Awards for 2025 > Prescrire Drug Awards for 2025 > Prescrire Drug Awards for 2025 > Prescrire's ratings for new drugs and new indications

The Prescrire Awards for 2025

Prescrire Drug Awards for 2025

The Prescrire Drug Awards for 2025
Prescrire's ratings for new drugs and new indications

PRESCRIRE'S RATINGS

Our ratings indicate whether a product represents a therapeutic advance in the relevant clinical situation. We consider not only the inherent value of each product in terms of its harm-benefit balance, but also its advantages and disadvantages relative to existing treatments. Note that the relative value of new products can vary from one country to another.
 

Bravo

BRAVO

A clear and major therapeutic advance in a particularly poorly served field.

A Real Advance

A REAL ADVANCE

An important therapeutic advance but with certain limitations.

Offers an advantage

OFFERS AN ADVANTAGE

Offers some value but does not fundamentally change current therapeutic practice.

Possibly helpful

POSSIBLY HELPFUL

Offers minimal additional value, and should not change prescribing habits except in rare circumstances.

Nothing new

NOTHING NEW

Not shown to represent a therapeutic advance.

Not acceptable

NOT ACCEPTABLE

Offers no evident benefit but has potential or real disadvantages.
 

Judgement reserved

JUDGEMENT RESERVED

The editors postpone their rating until better data and a more thorough evaluation of the product are available.

 

Le Palmarès de l'information
 The Prescrire Drug Awards for 2025


Download the full article:

Télécharger
 "The Prescrire Awards for 2025" Prescrire Int 2026; 35 (281): 134-138. FREE.

 

Back to "The Prescrire Awards for 2025"

©Prescrire May 2026      

Filet

Enjoy full access to Prescrire International, and support independent medical information